March 3, 2020
26-28 February 2020 InSysBio QSP-company held its 13th Annual Internal Scientific Meeting. InSysBio team presented the results of 2019 year professional progress. Every member demonstrated their personal achievements and shared the plans for the future development. Oleg Demin, InSysBio CEO and founder, summarized all the company’s advancement of the year 2019. In 2019 InSysBio focused on four therapeutic areas: oncology, immunology, immune-oncology and neurodegenerative diseases. The team managed to take part in four international conferences, namely, ACoP 10, AACR 2019, 15th Annual PEGS Summit and PAGE 2019. He also covered a diverse range of softs (qs3p 0.4.20, heta 0.2.4 etc), databases (Cytocon DB 1.0), QSP-tools (IRT 3.0.0), platforms and typical models that were developed or enhanced throughout the year. Moreover, the number of projects in collaboration with pharmaceutical giants has a significant growth within a three-year period (by 40%). The meeting was closed up by a heated discussion of the reports and plans vision.
Besides, the perspective outlook shows that the company has intention towards constant growth and it is depicted by the company’s goals for this year. Moreover, the methods to achieve it and the intermediate tasks were also set. Some new versions of databases and QSP-tools are going to be released in the nearest future. This year the company is presenting its results at ACoP 11, AAPS 2020, ASCPT 2020 and QSPC 2020. Follow our news to get informed about additional meetings participation that can be announced.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | July 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
1.
14 Jul 2017 18:49
To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created
Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
1.
25 Jul 2017 13:50
InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc.
Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
2.
25 Jul 2017 17:37
InSysBio will present at the American Conference on Pharmacometrics (ACoP8)!
Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
